Bio-Techne Corporation (TECH): A Bull Case Theory

We came across a bullish thesis on Bio-Techne Corporation on Valueinvestorsclub.com by rab. In this article, we will summarize the bulls’ thesis on TECH. Bio-Techne Corporation's share was trading at $64.63 as of November 26th. TECH’s trailing and forward P/E were 134.39 and 33.22  respectively, according to Yahoo Finance.

Bio-Techne, founded in 1976 and reshaped through a series of strategic pivots and acquisitions, has evolved into a global leader in life-science consumables and specialized tools supporting research, diagnostics, and emerging cell and gene therapies. Under CEO Kim Kelderman, who succeeded a planned transition in 2024, and long-time CFO Jim Hippel, the company operates with a performance-aligned compensation framework and maintains broad analyst coverage.

Bio-Techne generates most of its revenue from high-quality, premium-priced consumables, holding 30–40% share in cytokines and growth factors, ~5% share in antibodies, and a leadership position in cited proteins. Its portfolio spans reagents, assays, instruments, and proprietary platforms such as automated western blot systems and spatial biology tools, sold primarily direct-to-consumer but supported by distributor partnerships, including a long-standing relationship with Thermo Fisher. The business is diversified across pharma, biotech, academia, and diagnostics, with no customer concentration risk and exposure across the research-to-clinical continuum.

Competition is intense, yet Bio-Techne’s premium brand, scale advantages, and breadth of applications underpin its ability to take share in growing markets like precision medicine, biologics, and spatial biology. The company invests heavily in R&D and acquisitions, launching 800 new products in 2024 and expanding its TAM from $3B to ~$28B since 2013. Growth has been driven by both organic initiatives and disciplined M&A, including an anticipated full acquisition of Wilson Wolf.

Financial strength remains solid, with conservative leverage, strong free cash flow, and capacity for further deals. While risks include acquisition integration, funding cyclicality, and margin sensitivity in consumables, the current valuation reflects compressed multiples and cautious sentiment rather than deterioration in fundamentals. With improving funding conditions, demand normalization, and continued market-share gains, Bio-Techne offers a compelling opportunity near a cyclical low.

Previously we covered a bullish thesis on Bio-Techne Corporation by scuttleblurb in May 2025, which highlighted its diversified portfolio, cyclicality in commercial R&D, and early signs of recovery. The company's stock price has appreciated approximately by 34.8% since our coverage. This is because demand trends improved. The thesis still stands as core franchises remain solid. rab shares a similar view but emphasizes long-term TAM expansion.

Bio-Techne Corporation is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held TECH at the end of the second quarter which was 34 in the previous quarter. While we acknowledge the potential of TECH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.